THE EXPERT'S OPINION

Diversity, Equity, and Inclusion: Transforming the Landscape of Clinical Trials

Introduction

The imperative of diversity in clinical trials has been acknowledged not only by the United States Food and Drug Administration (FDA) as a legal requirement but also by various countries worldwide recognizing its crucial role in advancing scientific knowledge and ensuring comprehensive representation. In this regard, Marco Cid, the forward-thinking CEO of DROX CRO, has taken proactive measures to support this philosophy, exemplifying a commitment to equitable access. Notably, DROX has recently emerged as a Supporting Partner of the Association of Diversity in Clinical Trials (AOD), with Mr. Cid assuming a position on the AOD Advisory Board to further its mission.

Mission Statement

The primary mission of the AOD is to establish industry standards and best practices that enhance the representation of diverse participants in clinical trials. This objective will be accomplished through the development, integration, and meticulous monitoring of robust and consistent diversity methodologies across the research industry.

Upcoming Collaborative Effort

A seminal event bringing together multiple stakeholders will take place at the Drug Information Association conference in Boston, Massachusetts from June 25th to 27th. During this occasion, the importance of diversity in clinical trials will be emphasized through discussions and messaging within the clinical trials industry. The AOD will have a dedicated booth where constituents can engage with experts and exchange ideas. At this event, Dr. Jerome Adams, former US Surgeon General and Chairman of the Board, will address the partner meeting and will be available for a brief meet-and-greet in booth XXL.

Leadership and Impact

Dr. Diana Foster, President and Chief Diversity Officer of the AOD, expressed confidence in the transformative impact that Marco Cid and his team will have on this global issue, particularly in Mexico, by actively addressing diversity participation. It is acknowledged that each country faces distinct challenges in improving representation and defining the problem. The progressive stance of the CID Group underscores their dedication to increasing access for underrepresented populations.

Promoting Global Dialogue

As an illustrative example of the commitment to advancing diversity in clinical trials, the upcoming 2024 CLIR Summit in Mexico City in March will feature a dedicated breakout session focused on developing strategies and executing plans for inclusive trial design. Mr. Cid strongly encourages his Mexican counterparts involved in clinical research to join this influential gathering of industry partners. For more information on participation, interested individuals can contact Mr. Jeremy Mitchell, the Director of Business Development at the AOD, whose contact details are provided below.

Diana L. Foster, PhD

CEO and Chief Diversity Officer of the Association of Diversity. She is renowned for developing the influential Diversity Site Assessment Tool (DSAT). With six industry books and leading research studies on clinical site diversity, Dr. Foster is a highly soughtafter expert and recognized thought leader in diversity and clinical site best practices.

Jeremy Mitchell, MBA

Our Director of Business Development is a 25-year sales professional driven by a passion for diversity and making a positive impact. He actively contributes to Minorities in Clinical Research, advocating for diversity and inclusivity in healthcare. Jeremy firmly believes in the power of diversity to foster innovation, creativity, and excellence and remains dedicated to championing this cause in all aspects of his life.

Contact Information: Jeremy Mitchell, Director of Business Development, AOD, Email: jmitchell@associationofdiversity.org, Phone: 989-780-4244